The former leaders of SpringWorks Therapeutics are back with a new biotech venture that is already buzzing from a $300 ...
Bristol Myers Squibb has pulled the trigger on two neuroscience options, paying Prothena $55 million for a global license to a clinical-phase Alzheimer’s disease drug candidate and handing Evotec $40 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results